Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19743855 | 0.78 | TAAR1 (0.39) | MEP1BTAAR1KDM4EALDH1A1MAPK1 | |
| SCHEMBL17119690 | 0.78 | CA2 (0.42) | MEP1BTAAR1CA2CA4KDM4E | |
| SCHEMBL24180080 | 0.77 | HMGCR (0.37) | MEP1BTAAR1KDM4EALDH1A1HTR2A | |
| SCHEMBL34463045 | 0.77 | TAAR1 (0.52) | TAAR1KDM4EMAPK1HTR2AHTR2C | |
| SCHEMBL9873091 | 0.75 | KDM4E (0.43) | MEP1BCA1CA2CA4KDM4E | |
| SCHEMBL383805 | 0.75 | TRPA1 (0.32) | TAAR1KDM4EALDH1A1 | |
| SCHEMBL31719426 | 0.75 | HTR2A (0.41) | MAPK1HTR2AHTR2CHTR2B | |
| SCHEMBL12802009 | 0.75 | HTR2A (0.41) | MAPK1HTR2AHTR2CHTR2B | |
| SCHEMBL22391550 | 0.75 | MEP1B (0.32) | MEP1B | |
| SCHEMBL4592694 | 0.75 | MEP1B (0.51) | MEP1BHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714247-B2 | Multiple kinase pathway inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9714247-B2 | Multiple kinase pathway inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170107215-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-04-20 | — | — | US | disclosed |
| US-20170107215-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-04-20 | — | — | US | disclosed |
| US-9493454-B2 | Multiple kinase pathway inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493454-B2 | Multiple kinase pathway inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150266870-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | MANNKIND CORPORATION | 2015-09-24 | — | — | US | disclosed |
| US-20150266870-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | MANNKIND CORPORATION | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266870-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | MAP3K6, MAP3K2, MAP3K1 | MEP1B 1525/4885TAAR1 4579/4885CA1 4838/4885 |
| US-20170107215-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | MAP3K6, MAP3K2, MAP3K1 | MEP1B 1525/4885TAAR1 4579/4885CA1 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.